@article{MAKHILLRJP2018122-612506,
    title = {Do Histone Acetyltransferase Inhibitors Confer Neuroprotection Against
Neurodegenerative Disorders? An Overview},
    journal = {Research Journal of Pharmacology},
    volume = {12},
    number = {2-6},
    pages = {16-27},
    year = {2018},
    issn = {1815-9362},
    doi = {rjpharm.2018.16.27},
    url = {https://makhillpublications.co/view-article.php?issn=1815-9362&doi=rjpharm.2018.16.27},
    author = {Walter and},
    keywords = {Histone acetyltransferase inhibitors,neurodegenerative,disorders,idea,study,specific,support},
    abstract = {Histone acetyltransferase inhibitors are able to induce neuroprotection because of their antioxidant
properties, so, their therapeutic use in limiting neurological damage is strongly supported. Histone
acetyltransferase inhibitors treatments should not only aim to alleviate specific symptoms but also, attempt to
delay/arrest disease progression and to repair the damaged structures. The acetylation and deacetylation of
histones are involved in the regulation of gene expression and the regular function of Histone
Acetyltransferases (HATs) and Deacetylases (HDACs) provide regulatory steps for gene expression and cell
cycle. Functional defects of these enzymes may lead to several diseases, including neurodegenerative
disorders. The studies reported in the present review support the view that thehistone acetyltransferase
inhibitors may be a key modulatory element in the control of neurodegenerative disorders. This idea is
supported by different anatomical, electrophysiological, pharmacological and biochemical data. Furthermore,
these studies support the idea of developing novel pharmacotherapies with histone acetyltransferase inhibitors
that selectively target specific area of CNS.}
    }